Ultimovacs Asa

Good afternoon and welcome to Ultimavax Third Quarter 2024 Business Update and Financial Results. My name is Carlos de Souza and I'm the CEO. And as usual, I have with me Jens Bjørheim, our Chief Medical Officer, and Hans Vassgård, our Chief Financial Officer. If we can move to the next slide, just to show you briefly our disclaimer, and we continue to the next slide. So I will make a brief introduction. We will talk then about the clinical update for UV1, brief words about our novel drug conjugation platform, the financial update, and then the news flow. So if we can move to the next slide. This quarter was again, we had the disappointing news about the results from our focus trial in head and neck cancer.

We knew that Difficult target to have. Cancer is.

a very difficult cancer to treat, and even the standard of care has very low efficacy. But anyway, we were still disappointed, but as a company, we are still committed to bringing UV1 across the next important data point. That is a Duvac readout that we expect in the first half of 2025. The good news is that Duvac is enrolling patients quite nicely, 28 patients in the last quarter. And this good inclusion of patients is a good sign. And again, help us for the time being to keep the expected results in the first half of the next year. We also, in September, to communicate it, we stopped the recruitment of patients for the LUNVAC trial in lung cancer. And this discontinuation was due to the very slow rate of patient enrollment in the study. Anyway, the patients will be analyzed

and the results are expected in the first half of 2020. Thank you. market to We have been continuously working on trying to really behave Experiences. through the first quarter of 2026.

And with this, I give the word to Ian. Next slide.

Thank you, Carlos. Good afternoon. A short clinical update on the UV-1 program. On the next slide, you can see the clinical trials that we have conducted and is finalized and those that are still running. Our main indication is, as you know, malignant melanoma, and we have been part of four other trials in different indications. This is

for background information submit you can look it is Moving on to the next slide. And an update on the clinic. so the focus several stops at from the try that unfortunately was the negative back in August, was published online. in the end of October. And now it flows to be in paper format. ... ... ... ... ... ... ...

This trial is actively recruiting patients. The trial is in women with a BRCA-negative ovarian cancer, high grade, and it's treated in combination with Durvalumab and Olaparib. As of now, 148 patients are included in this trial, and the total number should be 184. We expect readout of this trial in the first half of 2025. In the Lundmark trial, we stopped recruitment in that trial in September.

It's a trial in non-small cell lung cancer where the Lundmark vaccine was used in a combination. We did a video on checkpoint inhibition. And 31 patients. Very good. September. And there we go. of the 31 patients will come first half of next year. All those patients have their ink. You did it. You did it. You did it. You did it. will be followed up after And the results will be reported in the first half of next year.

Moving on to the next, the drug congregation platform. Some bullets on that one as well, if you go to the next slide. So we are, as Carlos mentioned, continuing to evaluate our congregation technology. This is a technology that was originally developed to expand our vaccine pipeline. This is something that the CMC and research group in Ultimax has worked on for several years.

This communication technology has the possibility is to combine different molecules.